2762739-36-4

2762739-36-4 structure

Name: BT7480
Chemical Name: BT7480
CAS Number: 2762739-36-4
Molecular Formula: C₃₃₁H₄₆₇N₇₃O₈₉S₁₀
Molecular Weight: 7213.34
Catalog: Research Areas Cancer
Create Date: 2023-06-17 19:39:09
Modify Date: 2025-08-27 14:40:53
BT7480 (BCY11863) is one of the Bicycle tumor-targeted immune cell agonists (Bicycle TICAs). BT7480 is an angonist of CD137 (4-1BB). BT7480 consists of a poly(ethylene glycol) (PEG)-based linker, and a synthetic Bicycle peptide targeting CD137 conjugated to Bicycles targeting Nectin-4. Nectin-4 is a cell adhesion molecule, overexpressing in multiple tumor cells. BT7480 elicits significant CD137 agonism and potent antitumor activity in syngeneic mouse models[1][2].

Name	BT7480

Description	BT7480 (BCY11863) is one of the Bicycle tumor-targeted immune cell agonists (Bicycle TICAs). BT7480 is an angonist of CD137 (4-1BB). BT7480 consists of a poly(ethylene glycol) (PEG)-based linker, and a synthetic Bicycle peptide targeting CD137 conjugated to Bicycles targeting Nectin-4. Nectin-4 is a cell adhesion molecule, overexpressing in multiple tumor cells. BT7480 elicits significant CD137 agonism and potent antitumor activity in syngeneic mouse models[1][2].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Others >> Others
Target	CD137 (4-1BB)[1]
In Vitro	BT7480 导致原代人免疫细胞中促炎细胞因子 IFNγ 和 IL-2 的分泌呈剂量依赖性增加 (EC50=0.22 nM 和 0.36 nM)，而 HT1376 肿瘤细胞与来自健康供体的人外周血单核细胞 (PBMC) 共培养并用抗 CD3 处理以刺激 CD137 在免疫细胞上的表达[1]。
In Vivo	BT7480（5 mg/kg；腹腔注射；每天一次，持续 10 天）在 CT26-Nectin-4/huCD137 小鼠模型中表现出抗肿瘤活性[1]。 BT7480（2 mg/kg；静脉注射；单剂量）的 CL 为 8.5 mL/min/kg，终末半衰期为 3.6 小时[1]。 BT7480（1、5、10 和 30 mg/kg；腹腔注射；单剂量）导致 CD-1 小鼠的暴露量 (AUCinf) 剂量依赖性增加[1] 。 BT7480（1 和 10 mg/kg；腹腔注射；每天 3 次，持续 40 天）在小鼠 MC38-Nectin-4 肿瘤模型中导致肿瘤消退[1]。在食蟹猴 MC38 同基因模型中的药代动力学分析[1] Route Dose (mg/kg) CLlast (mL/min/kg) Vdss (L/kg) t1/2 (h) i.v. 1 3.3 0.62 5.3 Animal Model: Mice bearing subcutaneous MC38-Nectin-4 tumors[1] Dosage: 1 mg/kg and 10 mg/kg Administration: IP; 3 times per days for 40 days Result: Led efficacious tumor growth reduction and complete responses (CRs) induction, with the rate of CRs ranging from 4/6 (1 mg/kg) to 6/6 (10 mg/kg) by day 40.
References	[1]. Upadhyaya P, et al. Discovery and Optimization of a Synthetic Class of Nectin-4-Targeted CD137 Agonists for Immuno-oncology. J Med Chem. 2022 Jul 28;65(14):9858-9872. [2]. Hurov K, et al. A novel fully synthetic dual targeted Nectin-4/4-1BB Bicycle (R) peptide induces tumor localized 4-1BB agonism[J]. J. Immunother. Cancer, 2019, 7.

Molecular Formula	C₃₃₁H₄₆₇N₇₃O₈₉S₁₀
Molecular Weight	7213.34

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.

2640959-72-2	2640842-28-8
2640966-11-4	2640892-24-4
2640949-70-6	2327157-63-9
2640903-50-8	2137856-76-7
2743438-95-9	2648221-93-4